drugset / Trial / NCT02897869
DDI Study to Investigate Interaction Between Amikacin and POL7080
RandomizedCrossoverOpen-labelTreatment
Summary
Single-center, open-label, 2-sequence, 3-period crossover drug-drug interaction study. Repeated doses of POL7080 and repeated doses of amikacin will be administered alone or combined. In total, 14 subjects will be enrolled to obtain at least 10 evaluable subjects. The study consists of an eligibility screening period, up to 3 treatments periods and a follow-up visit.
Timeline
- Start
- 2016-04
- Primary completion
- 2016-08
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amikacin | Small molecule | — | — |
| Subject | Murepavadin | Peptide | — | — |
Indications
No indication recorded.